Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;34(4):713-724.
doi: 10.1007/s00198-023-06687-w. Epub 2023 Jan 31.

Metabolic associated fatty liver disease and bone mineral density: a cross-sectional study of the National Health and Nutrition Examination Survey 2017-2018

Jinmin Liu #  1   2   3 , Yuchen Tang #  1   2   3 , Zhiwei Feng  1   2   3 , Yi Chen  1   2   3 , Xiaohui Zhang  1   2   3 , Yayi Xia  1   2   3 , Bin Geng  4   5   6
Affiliations

Metabolic associated fatty liver disease and bone mineral density: a cross-sectional study of the National Health and Nutrition Examination Survey 2017-2018

Jinmin Liu et al. Osteoporos Int. 2023 Apr.

Abstract

This research is a cross-sectional study based on the participants aged 50 years and older from National Health and Nutrition Examination Survey (NHANES) database. The metabolic associated fatty liver disease (MAFLD) population has higher BMD and a lower risk of osteoporosis than those without MAFLD.

Introduction: MAFLD is a new definition presented by panel of experts based on non-alcoholic fatty liver disease in 2020. However, the link between MAFLD and bone mineral density (BMD) is uncertain. Thus, the present study aimed to investigate the relationship between MAFLD and BMD.

Methods: This cross-sectional study included subjects aged ≥ 50 years from the National Health and Nutrition Examination Survey 2017-2018. Multivariate linear regression models were performed to investigate the association between MAFLD and BMD. Moreover, the relationship between MAFLD and osteoporosis was assessed using multiple logistic regression models.

Results: Finally, 817 participants (non-MAFLD, n = 436; MAFLD, n = 381) were included in the final analysis. The results demonstrated that participants with MAFLD showed higher femoral BMDs than those without MAFLD, especially among males aged ≥ 50 years and females aged ≥ 65 years. Moreover, the results showed that obese men (BMI ≥ 30 kg/m2) with MAFLD had higher femoral BMDs than the control group according to subgroup analyses stratified by BMI, but this trend was not present in women. In addition, multiple logistic regression models showed that participants with MAFLD had no increased risks of osteoporosis.

Conclusion: The present study found that the MAFLD population has higher BMD and a lower risk of osteoporosis than those without MAFLD. Because the present study was a cross-sectional study, we could not identify the cause-effect relation between MAFLD and BMD. Therefore, additional research needs to be performed to explore the influences of MAFLD on bone metabolism in the future.

Keywords: Metabolic associated fatty liver disease; bone mineral density; osteoporosis.

PubMed Disclaimer

References

    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73–84 - PubMed - DOI
    1. Cotter TG, Rinella M (2020) Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology 158(7):1851–1864 - PubMed - DOI
    1. Ciardullo S, Perseghin G (2021) Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int 41(6):1290–1293 - PubMed - DOI
    1. Younossi ZM (2019) Non-alcoholic fatty liver disease — a global public health perspective. J Hepatol 70(3):531–544 - PubMed - DOI
    1. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM et al (2020) A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73(1):202–209 - PubMed - DOI

LinkOut - more resources